We are live on ! Find out more
VIGL

Vigil Neuroscience

Delisted

VIGL was delisted on the 4th of August, 2025.

52 hedge funds and large institutions have $94.5M invested in Vigil Neuroscience in 2024 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 13 increasing their positions, 18 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.38% more ownership

Funds ownership: 69.54%69.92% (+0.38%)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

10% less capital invested

Capital invested by funds: $105M → $94.5M (-$10.1M)

10% less funds holding

Funds holding: 5852 (-6)

28% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 18

38% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 16

Holders
52
Holders Change
-6
Holders Change %
-10.34%
% of All Funds
0.75%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
10
Increased
13
Reduced
18
Closed
16
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
AVLSA
1
Atlas Venture Life Science Advisors
Massachusetts
$19.8M
NV
2
Northpond Ventures
Maryland
$14.3M
SL
3
Siren LLC
Connecticut
$6.77M +$7.38M +1,991,038 New
BI
4
BVF Inc
California
$6.17M
SFM
5
Sphera Funds Management
Israel
$5.6M -$165K -44,562 -3%
Point72 Asset Management
6
Point72 Asset Management
Connecticut
$5.44M +$426K +115,000 +8%
DTC
7
Deep Track Capital
Connecticut
$5.28M +$3.54M +956,781 +160%
Citadel Advisors
8
Citadel Advisors
Florida
$4.9M -$2.56K -691 -0%
6CM
9
683 Capital Management
New York
$4.15M +$443K +119,580 +11%
Vanguard Group
10
Vanguard Group
Pennsylvania
$3.08M +$333K +90,000 +11%
SC
11
Stempoint Capital
New York
$2.53M -$2.57K -693 -0.1%
Ensign Peak Advisors
12
Ensign Peak Advisors
Utah
$2.06M +$779K +210,420 +53%
PBPIA
13
Pivotal bioVenture Partners Investment Advisor
California
$1.91M
RSCM
14
Rock Springs Capital Management
Maryland
$1.6M
O
15
OrbiMed
New York
$1.53M
BlackRock
16
BlackRock
New York
$1.44M +$64.8K +17,504 +4%
ACH
17
ArrowMark Colorado Holdings
Colorado
$984K
Millennium Management
18
Millennium Management
New York
$948K -$208K -56,051 -17%
Aberdeen Group
19
Aberdeen Group
United Kingdom
$799K +$871K +235,011 New
Geode Capital Management
20
Geode Capital Management
Massachusetts
$769K +$247K +66,712 +42%
WP
21
Woodline Partners
California
$490K -$231K -62,472 -30%
Marshall Wace
22
Marshall Wace
United Kingdom
$490K +$534K +144,042 New
Verition Fund Management
23
Verition Fund Management
Connecticut
$442K +$482K +130,030 New
Walleye Capital
24
Walleye Capital
New York
$407K +$342K +92,217 +334%
BCM
25
Bridgeway Capital Management
Texas
$357K +$92.6K +25,000 +31%

VIGL Hedge Fund Activity: Q3 2024 in Review

52 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Vigil Neuroscience (VIGL) for Q3 2024, worth a combined $94.5M — down 9.6% from $105M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of VIGL and 10 opened new positions — a net loss of 6 holders — while 18 trimmed existing stakes and 13 added.

The largest buyer was Deep Track Capital, adding an estimated $3.54M. The largest seller was Artal Group, exiting entirely with an estimated $7.31M sold.

  • 52 institutional investors held Vigil Neuroscience (VIGL) as of Q3 2024, down from 58 in Q2 2024.
  • Funds reported $94.5M of Vigil Neuroscience stock for Q3 2024, down 9.6% quarter-over-quarter.
  • 10 funds opened new Vigil Neuroscience positions in Q3 2024 and 16 closed out, a net change of -6 holders.
  • The largest Vigil Neuroscience buyer in Q3 2024 was Deep Track Capital, an estimated $3.54M added.
  • The largest Vigil Neuroscience seller in Q3 2024 was Artal Group, an estimated $7.31M sold.

Based on aggregated 13F filings for Q3 2024.